UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Ventricular arrhythmias and sudden death in patients taking ibrutinib

Blood, 2017-05, Vol.129 (18), p.2581-2584

2017

Link zum Volltext

Verfügbarkeit prüfen

Rare Codons Regulate KRas Oncogenesis

Current biology, 2013-01, Vol.23 (1), p.70-75

2013

Link zum Volltext

Verfügbarkeit prüfen

Activity of erlotinib when dosed below the maximum tolerated dose for EGFR‐mutant lung cancer: Implications for targeted therapy development

Cancer, 2016-11, Vol.122 (22), p.3456-3463

2016

Link zum Volltext

Verfügbarkeit prüfen

PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma

Expert opinion on investigational drugs, 2017-11, Vol.26 (11), p.1267-1279

2017

Link zum Volltext

Verfügbarkeit prüfen

Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer

PloS one, 2015-10, Vol.10 (10), p.e0140253-e0140253

2015

Link zum Volltext

Verfügbarkeit prüfen

Targeting eNOS in Pancreatic Cancer

Cancer research (Chicago, Ill.), 2012-09, Vol.72 (17), p.4472-4482

2012

Link zum Volltext

Verfügbarkeit prüfen

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?

Expert review of hematology, 2018-03, Vol.11 (3), p.185-194

2018

Link zum Volltext

Verfügbarkeit prüfen

The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia

Hematology/oncology clinics of North America, 2021-08, Vol.35 (4), p.807

2021

Link zum Volltext

Verfügbarkeit prüfen

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

The lancet oncology, 2021-10, Vol.22 (10), p.1391-1402

2021

Link zum Volltext

Verfügbarkeit prüfen

A new triple threat to CLL

Blood, 2018-10, Vol.132 (15), p.1547-1548

2018

Link zum Volltext

Verfügbarkeit prüfen

The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia

Current hematologic malignancy reports, 2017-02, Vol.12 (1), p.11-19

2017

Link zum Volltext

Verfügbarkeit prüfen

For CLL cells, there's no place like home

Leukemia & lymphoma, 2019-12, Vol.60 (14), p.3347-3349

2019

Link zum Volltext

Verfügbarkeit prüfen

Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2023-02, Vol.41 (5), p.1116-1128

2023

Link zum Volltext

Verfügbarkeit prüfen

Rare codons capacitate Kras-driven de novo tumorigenesis

The Journal of clinical investigation, 2015-01, Vol.125 (1), p.222-233

2015

Link zum Volltext

Verfügbarkeit prüfen

Tip of the Tongue

The New England journal of medicine, 2016-09, Vol.375 (9), p.880-886

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

Blood advances, 2019-04, Vol.3 (7), p.1167-1174

2019

Link zum Volltext

Verfügbarkeit prüfen

Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients

Blood, 2019-11, Vol.134 (Supplement_1), p.1731-1731

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract IA14: Rare codons capacitate Kras-driven de novo tumorigenesis

Cancer research (Chicago, Ill.), 2017-03, Vol.77 (6_Supplement), p.IA14-IA14

2017

Link zum Volltext

Verfügbarkeit prüfen

Characteristics of Rare Germline ATM Variants in Chronic Lymphocytic Leukemia (CLL)

Blood, 2022-11, Vol.140 (Supplement 1), p.9853-9854

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeting Oncoproteins with a Positive Selection Assay for Protein Degraders

Blood, 2020-11, Vol.136 (Supplement 1), p.13-14

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(35)

Publikationsform

Sprache

Englisch
(39)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Humans
(15)
Life Sciences & Biomedicine
(14)
Hematology
(8)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(7)
Mutation
(6)
Oncology
(6)
Animals
(5)
Chronic Lymphocytic Leukemia
(5)
Biochemistry
(3)
Cancer
(3)
Cell Biology
(3)
Female
(3)
Male
(3)
Mice, Transgenic
(3)
Aged
(2)
Antibodies, Monoclonal, Humanized
(2)
Antineoplastic Agents - Administration & Dosage
(2)
Antineoplastic Agents - Adverse Effects
(2)
Antineoplastic Agents - Pharmacology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(15)
Cancer Research
(3)
Cancer
(2)
Journal Of Clinical Oncology
(2)
Plos One
(2)
Blood Advances
(1)
Current Biology
(1)
Current Hematologic Malignancy Reports
(1)
Expert Opinion On Investigational Drugs
(1)
Expert Review Of Hematology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

Ventricular arrhythmias and sudden death in patients taking ibrutinib

Rare Codons Regulate KRas Oncogenesis

Activity of erlotinib when dosed below the maximum tolerated dose for EGFR‐mutant lung cancer: Implications for targeted therapy development

PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma

Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer

Targeting eNOS in Pancreatic Cancer

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?

The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

A new triple threat to CLL

The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia

For CLL cells, there's no place like home

Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia

Rare codons capacitate Kras-driven de novo tumorigenesis

Tip of the Tongue

Targeting oncoproteins with a positive selection assay for protein degraders

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients

Abstract IA14: Rare codons capacitate Kras-driven de novo tumorigenesis

Characteristics of Rare Germline ATM Variants in Chronic Lymphocytic Leukemia (CLL)

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Targeting Oncoproteins with a Positive Selection Assay for Protein Degraders

Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Suchergebnisse filtern